Skip to main content
SpringerLink
Log in

Management of Infantile Hemangiomas

Current and Potential Pharmacotherapeutic Approaches

  • Review Article
  • Published:
Pediatric Drugs Aims and scope Submit manuscript

Abstract

Infantile hemangiomas (IH), benign vascular neoplasms, are the most common tumors of infancy and childhood. Most IH are medically insignificant; however, a proportion will require treatment because of interference with vital structures, threat of significant disfigurement, ulceration, or bleeding. This article reviews current and potential pharmacotherapeutic approaches to the treatment of IH. While corticosteroids have long been considered the mainstay of medical therapy for IH, several new treatments have recently emerged, the most promising of which is oral propranolol. Topical timolol and imiquimod are additional new therapies that may also prove to be effective, particularly for the treatment of superficial IH.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Bowers RE, Graham EA, Tomlinson KM. The natural history of the strawberry nevus. Arch Dermatol. 1960;82:667–80.

    Article  Google Scholar 

  2. Haggstrom AN, Drolet BA, Baselga E, et al. Prospective study of infantile hemangiomas: clinical characteristics predicting complications and treatment. Pediatrics. 2006;118:882–7.

    Article  PubMed  Google Scholar 

  3. Holland KE, Drolet BA. Infantile hemangioma. Pediatr Clin North Am. 2010;57:1069–73.

    Article  PubMed  Google Scholar 

  4. Drolet BA, Esterly NB, Frieden IJ. Hemangiomas in children. N Engl J Med. 1999;341:173–81.

    Article  PubMed  CAS  Google Scholar 

  5. Greenberger S, Boscolo E, Adini I, et al. Corticosteroid suppression of VEGF-A in infantile hemangioma-derived stem cells. N Engl J Med. 2010;362:1005–13.

    Article  PubMed  CAS  Google Scholar 

  6. Bruckner AL, Frieden IJ. Hemangiomas of infancy. J Am Acad Dermatol. 2003;48:477–93 (quiz 94–6).

    Google Scholar 

  7. Sadan N, Wolach B. Treatment of hemangiomas of infants with high doses of prednisone. J Pediatr. 1996;128:141–6.

    Article  PubMed  CAS  Google Scholar 

  8. Enjolras O, Riche MC, Merland JJ, et al. Management of alarming hemangiomas in infancy: a review of 25 cases. Pediatrics. 1990;85:491–8.

    PubMed  CAS  Google Scholar 

  9. Bennett ML, Fleischer AB Jr, Chamlin SL, et al. Oral corticosteroid use is effective for cutaneous hemangiomas: an evidence-based evaluation. Arch Dermatol. 2001;137:1208–13.

    PubMed  CAS  Google Scholar 

  10. George ME, Sharma V, Jacobson J, et al. Adverse effects of systemic glucocorticosteroid therapy in infants with hemangiomas. Arch Dermatol. 2004;140:963–9.

    Article  PubMed  CAS  Google Scholar 

  11. Boon LM, MacDonald DM, Mulliken JB. Complications of systemic corticosteroid therapy for problematic hemangioma. Plast Reconstr Surg. 1999;104:1616–23.

    Article  PubMed  CAS  Google Scholar 

  12. Kelly ME, Juern AM, Grossman WJ, et al. Immunosuppressive effects in infants treated with corticosteroids for infantile hemangiomas. Arch Dermatol. 2010;146:767–74.

    Article  PubMed  CAS  Google Scholar 

  13. Aviles R, Boyce TG, Thompson DM. Pneumocystis carinii pneumonia in a 3-month-old infant receiving high-dose corticosteroid therapy for airway hemangiomas. Mayo Clin Proc. 2004;79:243–5.

    Article  PubMed  Google Scholar 

  14. Maronn ML, Corden T, Drolet BA. Pneumocystis carinii pneumonia in infant treated with oral steroids for hemangioma. Arch Dermatol. 2007;143:1224–5.

    PubMed  Google Scholar 

  15. Guillemot N, Blanchon S, Nathan N, et al. Pneumocystis jiroveci pneumonia during prolonged corticosteroid therapy in an immunocompetent infant. Rev Pneumol Clin. 2008;64:225–8.

    Article  PubMed  CAS  Google Scholar 

  16. Prasetyono TO, Djoenaedi I. Efficacy of intralesional steroid injection in head and neck hemangioma: a systematic review. Ann Plast Surg. 2011;66:98–106.

    Article  PubMed  CAS  Google Scholar 

  17. Chantharatanapiboon W. Intralesional corticosteroid therapy in hemangiomas: clinical outcome in 160 cases. J Med Assoc Thai. 2008;91(Suppl. 3):S90–6.

    PubMed  Google Scholar 

  18. Barrio VR, Drolet BA. Treatment of hemangiomas of infancy. Dermatol Ther. 2005;18:151–9.

    Article  PubMed  Google Scholar 

  19. Maguiness SM, Frieden IJ. Current management of infantile hemangiomas. Semin Cutan Med Surg. 2010;29:106–14.

    Article  PubMed  CAS  Google Scholar 

  20. Egbert JE, Schwartz GS, Walsh AW. Diagnosis and treatment of an ophthalmic artery occlusion during an intralesional injection of corticosteroid into an eyelid capillary hemangioma. Am J Ophthalmol. 1996;121:638–42.

    PubMed  CAS  Google Scholar 

  21. Shorr N, Seiff SR. Central retinal artery occlusion associated with periocular corticosteroid injection for juvenile hemangioma. Ophthalmic Surg. 1986;17:229–31.

    PubMed  CAS  Google Scholar 

  22. Garzon MC, Lucky AW, Hawrot A, et al. Ultrapotent topical corticosteroid treatment of hemangiomas of infancy. J Am Acad Dermatol. 2005;52:281–6.

    Article  PubMed  Google Scholar 

  23. Leaute-Labreze C, Dumas de la Roque E, Hubiche T, et al. Propranolol for severe hemangiomas of infancy. N Engl J Med. 2008;358:2649–51.

    Article  PubMed  CAS  Google Scholar 

  24. Sans V, de la Roque ED, Berge J, et al. Propranolol for severe infantile hemangiomas: follow-up report. Pediatrics. 2009;124:e423–31.

    Article  PubMed  Google Scholar 

  25. Kim LH, Hogeling M, Wargon O, et al. Propranolol: useful therapeutic agent for the treatment of ulcerated infantile hemangiomas. J Pediatr Surg. 2011;46:759–63.

    Article  PubMed  Google Scholar 

  26. Saint-Jean M, Leaute-Labreze C, Mazereeuw-Hautier J, et al. Propranolol for treatment of ulcerated infantile hemangiomas. J Am Acad Dermatol. 2011;64:827–32.

    Article  PubMed  CAS  Google Scholar 

  27. Marsciani A, Pericoli R, Alaggio R, et al. Massive response of severe infantile hepatic hemangioma to propanolol [letter]. Pediatr Blood Cancer. 2010;54:176.

    Article  PubMed  Google Scholar 

  28. Mazereeuw-Hautier J, Hoeger PH, Benlahrech S, et al. Efficacy of propranolol in hepatic infantile hemangiomas with diffuse neonatal hemangiomatosis. J Pediatr. 2010;157:340–2.

    Article  PubMed  Google Scholar 

  29. Sarialioglu F, Erbay A, Demir S. Response of infantile hepatic hemangioma to propranolol resistant to high-dose methylprednisolone and interferon-alpha therapy. Pediatr Blood Cancer. 2010;55:1433–4.

    Article  PubMed  Google Scholar 

  30. Peridis S, Pilgrim G, Athanasopoulos I, et al. A meta-analysis on the effectiveness of propranolol for the treatment of infantile airway haemangiomas. Int J Pediatr Otorhinolaryngol. 2011;75:455–60.

    Article  PubMed  Google Scholar 

  31. Rosbe KW, Suh KY, Meyer AK, et al. Propranolol in the management of airway infantile hemangiomas. Arch Otolaryngol Head Neck Surg. 2010;136:658–65.

    Article  PubMed  Google Scholar 

  32. Buckmiller L, Dyamenahalli U, Richter GT. Propranolol for airway hemangiomas: case report of novel treatment. Laryngoscope. 2009;119:2051–4.

    Article  PubMed  Google Scholar 

  33. Lawley LP, Siegfried E, Todd JL. Propranolol treatment for hemangioma of infancy: risks and recommendations. Pediatr Dermatol. 2009;26:610–4.

    Article  PubMed  Google Scholar 

  34. Leaute-Labreze C, Taieb A. Efficacy of beta-blockers in infantile capillary haemangiomas: the physiopathological significance and therapeutic consequences. Ann Dermatol Venereol. 2008;135:860–2.

    Article  PubMed  CAS  Google Scholar 

  35. Frieden IJ, Drolet BA. Propranolol for infantile hemangiomas: promise, peril, pathogenesis. Pediatr Dermatol. 2009;26:642–4.

    Article  PubMed  Google Scholar 

  36. SommersSmith SK, Smith DM. Beta blockade induces apoptosis in cultured capillary endothelial cells. In Vitro Cell Dev Biol Anim. 2002;38:298–304.

    Article  CAS  Google Scholar 

  37. Itinteang T, Brasch HD, Tan ST, et al. Expression of components of the renin-angiotensin system in proliferating infantile haemangioma may account for the propranolol-induced accelerated involution. J Plast Reconstr Aesthet Surg. 2011;64:759–65.

    Article  PubMed  Google Scholar 

  38. Breur JM, de Graaf M, Breugem CC, et al. Hypoglycemia as a result of propranolol during treatment of infantile hemangioma: a case report. Pediatr Dermatol. 2011;28:169–71.

    Article  PubMed  Google Scholar 

  39. Holland KE, Frieden IJ, Frommelt PC, et al. Hypoglycemia in children taking propranolol for the treatment of infantile hemangioma. Arch Dermatol. 2010;146:775–8.

    Article  PubMed  CAS  Google Scholar 

  40. Manunza F, Syed S, Laguda B, et al. Propranolol for complicated infantile haemangiomas: a case series of 30 infants. Br J Dermatol. 2010;162:466–8.

    Article  PubMed  CAS  Google Scholar 

  41. Pavlakovic H, Kietz S, Lauerer P, et al. Hyperkalemia complicating propranolol treatment of an infantile hemangioma. Pediatrics. 2010;126:e1589–93.

    Article  PubMed  Google Scholar 

  42. Guo S, Ni N. Topical treatment for capillary hemangioma of the eyelid using beta-blocker solution. Arch Ophthalmol. 2010;128:255–6.

    Article  PubMed  Google Scholar 

  43. Pope E, Chakkittakandiyil A. Topical timolol gel for infantile hemangiomas: a pilot study. Arch Dermatol. 2010;146:564–5.

    Article  PubMed  Google Scholar 

  44. Khunger N, Pahwa M. Dramatic response to topical timolol lotion of a large hemifacial infantile haemangioma associated with PHACE syndrome. Br J Dermatol. 2011;164:886–8.

    Article  PubMed  CAS  Google Scholar 

  45. Ni N, Langer P, Wagner R, et al. Topical timolol for periocular hemangioma: report of further study. Arch Ophthalmol. 2011;129:377–9.

    Article  PubMed  Google Scholar 

  46. Sidbury R, Neuschler N, Neuschler E, et al. Topically applied imiquimod inhibits vascular tumor growth in vivo. J Invest Dermatol. 2003;121:1205–9.

    Article  PubMed  CAS  Google Scholar 

  47. Welsh O, Olazaran Z, Gomez M, et al. Treatment of infantile hemangiomas with short-term application of imiquimod 5% cream. J Am Acad Dermatol. 2004;51:639–42.

    Article  PubMed  Google Scholar 

  48. Ho NT, Lansang P, Pope E. Topical imiquimod in the treatment of infantile hemangiomas: a retrospective study. J Am Acad Dermatol. 2007;56:63–8.

    Article  PubMed  Google Scholar 

  49. Hazen PG, Carney JF, Engstrom CW, et al. Proliferating hemangioma of infancy: successful treatment with topical 5% imiquimod cream. Pediatr Dermatol. 2005;22:254–6.

    Article  PubMed  Google Scholar 

  50. McCuaig CC, Dubois J, Powell J, et al. A phase II, open-label study of the efficacy and safety of imiquimod in the treatment of superficial and mixed infantile hemangioma. Pediatr Dermatol. 2009;26:203–12.

    Article  PubMed  Google Scholar 

  51. Tamayo L, Ortiz DM, Orozco-Covarrubias L, et al. Therapeutic efficacy of interferon alfa-2b in infants with life-threatening giant hemangiomas. Arch Dermatol. 1997;133:1567–71.

    Article  PubMed  CAS  Google Scholar 

  52. Ezekowitz RA, Mulliken JB, Folkman J. Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med. 1992;326:1456–63.

    Article  PubMed  CAS  Google Scholar 

  53. Barlow CF, Priebe CJ, Mulliken JB, et al. Spastic diplegia as a complication of interferon Alfa-2a treatment of hemangiomas of infancy. J Pediatr. 1998;132:527–30.

    Article  PubMed  CAS  Google Scholar 

  54. Dubois J, Hershon L, Carmant L, et al. Toxicity profile of interferon alfa-2b in children: a prospective evaluation. J Pediatr. 1999;135:782–5.

    Article  PubMed  CAS  Google Scholar 

  55. Michaud AP, Bauman NM, Burke DK, et al. Spastic diplegia and other motor disturbances in infants receiving interferon-alpha. Laryngoscope. 2004;114:1231–6.

    Article  PubMed  CAS  Google Scholar 

  56. Enjolras O, Breviere GM, Roger G, et al. Vincristine treatment for function- and life-threatening infantile hemangioma. Arch Pediatr. 2004;11:99–107.

    Article  PubMed  CAS  Google Scholar 

  57. Perez J, Pardo J, Gomez C. Vincristine: an effective treatment of corticoid-resistant life-threatening infantile hemangiomas. Acta Oncol. 2002;41:197–9.

    Article  PubMed  Google Scholar 

  58. Moore J, Lee M, Garzon M, et al. Effective therapy of a vascular tumor of infancy with vincristine. J Pediatr Surg. 2001;36:1273–6.

    Article  PubMed  CAS  Google Scholar 

  59. Fawcett SL, Grant I, Hall PN, et al. Vincristine as a treatment for a large haemangioma threatening vital functions. Br J Plast Surg. 2004;57:168–71.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

No sources of funding were used to prepare this manuscript. The authors have no conflicts of interest that are directly relevant to the content of this review.

Author information

Authors and Affiliations

  1. Department of Dermatology, Yale University School of Medicine, P.O. Box 208059, New Haven, CT, 06520, USA

    Brittany G. Craiglow & Richard J. Antaya

Authors
  1. Brittany G. Craiglow
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Richard J. Antaya
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Brittany G. Craiglow.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Craiglow, B.G., Antaya, R.J. Management of Infantile Hemangiomas. Pediatr Drugs 15, 133–138 (2013). https://doi.org/10.1007/s40272-013-0008-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40272-013-0008-6

Keywords

Search

Navigation